In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: Microbiology profiling studies with staphylococci and streptococci

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2324-2334

  Robertson, Gregory T ^a   Bonventre, Eric J ^a,b   Doyle, Timothy B ^a,c   Du, Qun ^a   Duncan, Leonard ^a,c   Morris, Timothy W ^a,d   Roche, Eric D ^a,e   Yan, Dalai ^a,f   Lynch, A Simon ^a  

^a Cumbre Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

^d BAUSCH AND LOMB   (United States)

^e Healthpoint Ltd   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CARRIER PROTEIN; CBR 2092; MOXIFLOXACIN; PROTEIN MEPA; PROTEIN NORA; QUINOLONE; RIFAMPICIN; RIFAMYCIN;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM MUTANT; CELL DENSITY; CELL LINE; CULTURE MEDIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACOPHORE; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; QUINOLONES; RIFAMYCINS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS;

EID: 46249112774     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01651-07     Document Type: Article

References (28)

1. Aeschlimann, J. R., L. D. Dresser, G. W. Kaatz, and M. J. Rybak. 1999. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:335-340.
2. Bae, T., and O. Schneewind. 2006. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55:58-63.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 7th ed. CLSI document M7-A7, vol. 26, no. 2. Clinical and Laboratory Standards Institute, Wayne, PA.
4. DeMarco, C. E., L. A. Cushing, E. Frempong-Manso, S. M. Seo, T. A. A. Jaravaza, and G. W. Kaatz. 2007. Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 51:3235-3239.
5. Drlica, K. 2003. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52:11-17.
6. Drlica, K., and D. C. Hooper. 2003. Mechanisms of quinolone action, p. 19-40. In D. C. Hooper and E. Rubinstein (ed.), Quinolone antimicrobial agents, 3rd ed. ASM Press, Washington, DC.
7. Drlica, K., and M. Malik. 2003. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 3:249-282.
8. Drlica, K., M. Malik, R. J. Kerns, and X. Zhao. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392.
9. Du, Q., E. J. Bonventre, T. B. Doyle, L. Duncan, G. T. Robertson, E. D. Roche, and A. S. Lynch. 2007. In vitro microbiology profiling studies of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, abstr. F1-2103. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Garzoni, C., P. Francois, A. Huyghe, S. Couzinet, C. Tapparel, Y. Charbonnier, A. Renzoni, S. Lucchini, D. P. Lew, P. Vaudaux, W. L. Kelley, and J. Schrenzel. 2007. A global view of Staphylococcus aureus whole genome expression upon internalization in human epithelial cells. BMC Genomics 8:171.
11. Kaatz, G. W., V. V. Moudgal, and S. M. Seo. 2002. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J. Antimicrob. Chemother. 50:833-838.
12. Katayama, Y., H. Z. Zhang, and H. F. Chambers. 2003. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics. Microb. Drug Resist. 9:329-336.
13. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, S. K. Fridkin, and Active Bacterial Core Surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
14. Lynch, A. S., E. J. Bonventre, T. B. Doyle, Q. Du, L. Duncan, G. T. Robertson, and E. D. Roche. 2007. In vitro mode-of-action studies of CBR-2092: a novel rifamycin-quinolone hybrid antibiotic, abstr. F1-2101. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. Malik, M., T. Lu, X. Zhao, A. Singh, C. M. Hattan, J. Domagala, R. Kerns, and K. Drlica. 2005. Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol. Antimicrob. Agents Chemother. 49:2008-2014.
16. Moran, G. J., A. Krishnadasan, R. J. Gorwitz, G. E. Fosheim, L. K. McDougal, R. B. Carey, D. A. Talan, and the Emergency ID Net Study Group. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
17. Pillar, C. M., D. C. Draghi, D. J. Sheehan, and D. F. Sahm. 2007. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the. 2004 to 2005 LEADER Surveillance Programs. Diagn. Microbiol. Infect. Dis. 60:221-224.
18. Plouin-Gaudon, I., S. Clement, E. Huggler, C. Chaponnier, P. François, D. Lew, J. Schrenzel, P. Vaudaux, and J. S. Lacroix. 2006. Intracellular residency is frequently associated with recurrent Staphylococcus aureus rhinosinusitis. Rhinology 44:249-254.
19. Proctor, R. A., C. von Eiff, B. C. Kahl, K. Becker, P. McNamara, M. Herrmann, and G. Peters. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol 4:295-305.
20. Robertson, G. T., E. J. Bonventre, T. B. Doyle, Q. Du, L. Duncan, T. W. Morris, E. D. Roche, D. Yan, and A. S. Lynch. 2008. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2313-2323.
21. Robertson, G. T., E. J. Bonventre, T. B. Doyle, Q. Du, L. Duncan, E. D. Roche, and A. S. Lynch. 2007. Comparative in vitro activity of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and rifampin + quinolone combinations, abstr. F1-2102. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
22. Schmitz, F., A. Fluit, M. Luckefahr, B. Engler, B. Hofmann, J. Verhoef, H. Heinz, U. Hadding, and M. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42:807-810.
23. Schmitz, F. J., A. C. Fluit, S. Brisse, J. Verhoef, K. Kohrer, and D. Milatovic. 1999. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26:281-287.
24. Stubbings, W., J. Bostock, E. Ingham, and I. Chopra. 2005. Deletion of the multiple-drug efflux pump AcrAB in Escherichia coli prolongs the postantibiotic effect. Antimicrob. Agents Chemother. 49:1206-1208.
25. Tanaka, M., T. Wang, Y. Onodera, Y. Uchida, and K. Sato. 2000. Mechanism of quinolone resistance in Staphylococcus aureus. J. Infect. Chemother. 6:131-139.
26. Vaudaux, P., P. Francois, C. Bisognano, W. L. Kelley, D. P. Lew, J. Schrenzel, R. A. Proctor, P. J. McNamara, G. Peters, and C. Von Eiff. 2002. Increased expression of clumping factor and fibronectin-binding proteins by hemb mutants of Staphylococcus aureus expressing small colony variant phenotypes. Infect. Immun. 70:5428-5437.
27. von Eiff, C., C. Heilmann, R. A. Proctor, C. Woltz, G. Peters, and F. Gotz. 1997. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J. Bacteriol. 179:4706-4712.
28. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565.